| Texto completo | |
| Autor(es): |
Carvalho, Noemia Barbosa
;
de Freitas, Vera Lucia Teixeira
;
Aikawa, Nadia Emi
;
Vieira, Lucas Teixeira
;
Bezerra, Rita Cristina
;
de Proenca, Adriana Coraccini Tonacio
;
Bonfiglioli, Karina
;
Nakanishi, Erika Yoshie Shimoda
;
Higashino, Hermes Ryoiti
;
Shikanai-Yasuda, Maria Aparecida
Número total de Autores: 10
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Revista da Sociedade Brasileira de Medicina Tropical; v. 58, p. 7-pg., 2025-01-01. |
| Resumo | |
Patients with chronic Chagas disease (CD) and autoimmune rheumatic disorders (ARD) receiving immunosuppressive therapy are at risk for CD reactivation (CDR). This study monitored parasitemia over 9-121 months in six patients with CD and ARD using conventional and quantitative PCR and parasitology. Five patients showed parasitemia; two had elevated levels of parEq/mL (49-458.7). One patient received benznidazole with a marked decrease in parasitemia; in the other, treatment was discontinued after 12 days due to toxicity. No CDR occurred. These findings support the need for qPCR standardization for preemptive therapy and suggest that benznidazole may prevent CDR in patients with high parasitemia. (AU) | |
| Processo FAPESP: | 12/50273-0 - Monitoramento de pacientes imunodeprimidos com Doenças de Chagas: níveis de parasitemia e associação com o perfil, poliformismo de citonas sobrevidas e características dos isolados Trypanosoma cruzi em transplante de órgãos, uso de drogas imunossupressoras e co-infecção com o vírus da imunodeficiência humana |
| Beneficiário: | Maria Aparecida Shikanai Yasuda |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |